Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of ginsenoside Rb1 in preparing medicine for treating dilated cardiomyopathy

A technology of dilated cardiomyopathy and ginsenosides, which is applied in the field of medicine, can solve the problems that ginsenoside Rb1 has not been reported, and achieve high development and application value, reduce expression, and reduce the effect of progressive expansion

Active Publication Date: 2012-07-18
INST OF LAB ANIMAL SCI CHINESE ACAD OF MEDICAL SCI
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] And ginsenoside Rb1 (C 54 h 92 o 23 ·H 2 O) is a known chemical monomer present in many plants such as ginseng. Its structure and relevant biological activity have been reported in relevant textbooks and published literature, but ginsenoside Rb1 is used as a preparation for treating dilated cardiomyopathy. The use has not been reported so far

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of ginsenoside Rb1 in preparing medicine for treating dilated cardiomyopathy
  • Use of ginsenoside Rb1 in preparing medicine for treating dilated cardiomyopathy
  • Use of ginsenoside Rb1 in preparing medicine for treating dilated cardiomyopathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Effect of long-term administration of ginsenoside Rb1 on the survival rate of dilated heart disease model mice:

[0025] 1. cTnT R141W PCR identification of transgenic positive mice:

[0026] 1) Cut 0.5-1cm mouse tail and put it in EP tube, add 0.5ml mouse tail lysate, then add 20mg / ml proteinase K10μl, shake overnight at 55℃;

[0027] 2) The next day, add 300 μl saturated sodium chloride, let stand on ice for 15 minutes, and centrifuge at 13000 rpm for 15 minutes;

[0028] 3) Take 600 μl of the supernatant, add an equal volume of isopropanol, invert and mix until flocculent precipitates appear, and centrifuge at 13,000 rpm for 15 minutes;

[0029] 4) Wash the precipitate once with 70% ethanol, and dry the precipitate for about 30 minutes but not completely dry;

[0030] 5) The precipitate was dissolved in 200 μl TE, and the DNA was completely dissolved at 55°C for 2 hours;

[0031] 6) PCR (polymerase chain reaction) system:

[0032] 10X PCR Buffer (buffer) 2μl

...

Embodiment 2

[0046] Effects of long-term administration of ginsenoside Rb1 on cardiac function and configuration in model mice with dilated heart disease (ultrasound):

[0047]Echocardiography was performed once a month, under tribromoethanol anesthesia, and a small animal ultrasound instrument (Vevo770 small animal ultrasound detection system, Canada) was used to scan the probe at 30 MHz. The long-axis M-ultrasound results of the left ventricle were analyzed by echocardiography. Heart shape and heart function of animals in each group, including BW (body weight, body weight), LVPW; d (thickness of left ventricular posterior wall in diastole), LVPW; s (thickness of left ventricular posterior wall in systole), LVAW; d (diastolic left ventricular anterior wall thickness), LVAW; s (systolic left ventricular anterior wall thickness), LV Mass(AW) (left ventricular weight), Diameter; s (systolic left ventricular diameter), Diameter; d( Diastolic left ventricular diameter), Volume; s (systolic lef...

Embodiment 3

[0052] Effects of long-term administration of ginsenoside Rb1 on the microstructure of the heart of the model mice with dilated heart disease (HE and Masson staining):

[0053] 1. Method:

[0054] 1) The heart was fixed, paraffin sectioned, and routinely dewaxed to water;

[0055] 2) Conventional HE staining;

[0056] 3) Asson composite staining solution for 5 minutes;

[0057] 4) Rinse slightly with 0.2% acetic acid aqueous solution;

[0058] 5) 5% phosphotungstic acid for 5-10 minutes;

[0059] 6) Dip and wash twice with 0.2% acetic acid aqueous solution;

[0060] 7) Brilliant green staining solution for 5 minutes. 0.2% acetic acid aqueous solution soaking twice;

[0061] 8) Dehydrated with absolute ethanol, transparent with xylene, and sealed with neutral gum;

[0062] 9) Observation under a light microscope: collagen fibers are green, muscle fibers are red, and red blood cells are orange.

[0063] 2. Results:

[0064] Observed under the light microscope, the myoca...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the medicine field and provides an application of ginsenoside Rb1 in preparing medicine used for the treatment of dilated cardiomyopathy. The ginsenoside has the following functions: after long-term medicine delivery, the mortality of genetic dilated cardiomyopathy is reduced; the cardiac function of dilated cardiomyopathy is improved; the dilation of left ventricular is reduced; the myocardial cell hypertrophy and interstitial collagen hyperplasia of dilated cardiomyopathy are reduced; problems of uneven thickness of myocardial fiber, disorder arrangement, mitochondrial swelling, cristae rupture, sarcoplasmic reticulum dilation and broken intercalated disc connection found in the dilated cardiomyopathy are reduced; the expression of myocardial cell connexin Cx40 is improved; the expressions of cadherin E-cadherin and P-cadherin are improved; the expressions of fibroblast growth factors including FGF2, FGF7, FGF8 and FGF10 are enhanced. The expressions of integrin Itga8, Itgbp are reduced.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to the application of ginsenoside Rb1 as a medicine for treating dilated cardiomyopathy. Background technique [0002] Dilated cardiomyopathy is a myocardial disease mainly characterized by ventricular dilation and impaired myocardial systolic function. The clinical manifestations are progressive heart failure, arrhythmia, thromboembolism, and even sudden death. The prognosis is extremely poor, and the 5-year survival rate Less than 50%. The typical pathological features are dilation of ventricular cavity, thinning of heart wall, and apoptosis of cardiomyocytes. The main etiology is viral myocarditis and gene mutation, accounting for 70% of the incidence of dilated cardiomyopathy. [0003] A variety of mutated genes associated with dilated cardiomyopathy have been found in clinical studies, but most gene mutations can cause HCM and DCM at the same time, while the R141W mutation ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/704A61P9/04A61P9/06
CPCA61K31/704A61P9/00A61P9/04A61P9/06
Inventor 张连峰赵海萍秦川李万波
Owner INST OF LAB ANIMAL SCI CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com